BRIEF — GSK submits first filing for triple COPD therapy in Japan

UK pharma major GlaxoSmithKline and its partner Innoviva have submitted a regulatory application to the Japanese Ministry of Health, Labour and Welfare for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to treat adults with chronic obstructive pulmonary disorder (COPD).

This is the first regulatory filing to be made for a triple COPD therapy in a single inhaler in Japan, where more than five million people are affected by the respiratory condition.

Trelegy Ellipta is already licensed for use in the USA, European Union and a number of other countries under the same brand name.